Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.18
GRFS's Cash to Debt is ranked higher than
50% of the 308 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. GRFS: 0.18 )
GRFS' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 0.18

Equity to Asset 0.31
GRFS's Equity to Asset is ranked higher than
51% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. GRFS: 0.31 )
GRFS' s 10-Year Equity to Asset Range
Min: 0.28   Max: 0.37
Current: 0.31

0.28
0.37
Interest Coverage 3.07
GRFS's Interest Coverage is ranked higher than
52% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.96 vs. GRFS: 3.07 )
GRFS' s 10-Year Interest Coverage Range
Min: 1.56   Max: 18.28
Current: 3.07

1.56
18.28
F-Score: 7
Z-Score: 2.39
M-Score: -2.38
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 26.85
GRFS's Operating margin (%) is ranked higher than
95% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.30 vs. GRFS: 26.85 )
GRFS' s 10-Year Operating margin (%) Range
Min: 15.53   Max: 26.85
Current: 26.85

15.53
26.85
Net-margin (%) 12.60
GRFS's Net-margin (%) is ranked higher than
85% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.08 vs. GRFS: 12.60 )
GRFS' s 10-Year Net-margin (%) Range
Min: 2.8   Max: 16.2
Current: 12.6

2.8
16.2
ROE (%) 16.44
GRFS's ROE (%) is ranked higher than
91% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. GRFS: 16.44 )
GRFS' s 10-Year ROE (%) Range
Min: 3.03   Max: 26.13
Current: 16.44

3.03
26.13
ROA (%) 5.92
GRFS's ROA (%) is ranked higher than
77% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. GRFS: 5.92 )
GRFS' s 10-Year ROA (%) Range
Min: 0.89   Max: 8.93
Current: 5.92

0.89
8.93
ROC (Joel Greenblatt) (%) 44.16
GRFS's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 298 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.70 vs. GRFS: 44.16 )
GRFS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 15.23   Max: 44.16
Current: 44.16

15.23
44.16
» GRFS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

GRFS Guru Trades in Q2 2013

Steven Cohen 236,972 sh (New)
Jim Simons 1,370,654 sh (+49.28%)
Steve Mandel 4,439,693 sh (+0.13%)
Mario Gabelli 23,968 sh (unchged)
John Paulson 19,786,279 sh (-1.34%)
Ron Baron 27,000 sh (-26.73%)
» More
Q3 2013

GRFS Guru Trades in Q3 2013

Steve Mandel 4,453,500 sh (+0.31%)
John Paulson 19,838,107 sh (+0.26%)
Mario Gabelli 23,968 sh (unchged)
Ron Baron 27,000 sh (unchged)
Jim Simons 1,342,654 sh (-2.04%)
Steven Cohen 208,568 sh (-11.99%)
» More
Q4 2013

GRFS Guru Trades in Q4 2013

Caxton Associates 35,305 sh (New)
Mario Gabelli 29,977 sh (+25.07%)
Ron Baron 27,000 sh (unchged)
Steve Mandel Sold Out
Steven Cohen Sold Out
John Paulson 19,823,407 sh (-0.07%)
Jim Simons 550,702 sh (-58.98%)
» More
Q1 2014

GRFS Guru Trades in Q1 2014

Steven Cohen 456,098 sh (New)
Ron Baron 44,757 sh (+65.77%)
John Paulson 19,814,807 sh (-0.04%)
Mario Gabelli 29,777 sh (-0.67%)
Jim Simons 493,102 sh (-10.46%)
Caxton Associates 25,800 sh (-26.92%)
» More
» Details

Insider Trades

Latest Guru Trades with GRFS

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2014-03-31 Add 65.77%$34.91 - $42.83 $ 42.056%44757
Steve Mandel 2013-12-31 Sold Out 0.6%$28.78 - $36.23 $ 42.0531%0
Mario Gabelli 2013-12-31 Add 25.07%$28.78 - $36.23 $ 42.0531%29977
Ron Baron 2013-06-30 Reduce -26.73%$25.84 - $31.23 $ 42.0550%27000
Steve Mandel 2012-12-31 Add 1919.04%0.67%$22.46 - $25.27 $ 42.0580%4437327
John Paulson 2012-12-31 Add 23.16%0.6%$22.46 - $25.27 $ 42.0580%20179935
Ron Baron 2012-12-31 Reduce -22.3%$22.46 - $25.27 $ 42.0580%38850
John Paulson 2012-09-30 Add 46.23%0.98%$9.66 - $22.92 $ 42.05131%16385799
Steve Mandel 2012-09-30 New Buy0.03%$9.66 - $22.92 $ 42.05131%219774
Ron Baron 2012-09-30 Reduce -50%$9.66 - $22.92 $ 42.05131%50000
Mario Gabelli 2012-09-30 New Buy$9.66 - $22.92 $ 42.05131%27820
Mario Gabelli 2012-06-30 Sold Out 0.0031%$7.8 - $9.68 $ 42.05381%0
Ron Baron 2012-03-31 Add 25%$5.38 - $7.8 $ 42.05568%100000
Steve Mandel 2011-12-31 Sold Out 0.37%$4.52727 - $6.06364 $ 42.05680%0
Steve Mandel 2011-09-30 New Buy0.37%$5.02 - $7.39 $ 42.05558%7067971
John Paulson 2011-09-30 Reduce -21.85%0.08%$5.02 - $7.39 $ 42.05558%11150000
Ron Baron 2011-09-30 New Buy$5.02 - $7.39 $ 42.05558%65000
John Paulson 2011-06-30 New Buy0.37%$6.29 - $6.95 $ 42.05544%14266995
Mario Gabelli 2011-06-30 New Buy$6.29 - $6.95 $ 42.05544%50583
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Grifols SA

Baron Funds Comments on Grifols SA - Aug 30, 2012

From Baron Funds' second quarter commentary:

Grifols SA (GRFS) manufactures and sells plasma derivative healthcare products to hospitals and physicians globally. Grifols' NASDAQ-traded ADR increased over 24% during the quarter. Grifols' plasma proteins are an essential medical treatment for patients with primary immune deficiency, neurological diseases or hemophilia. Few companies can manufacture these treatments with a high degree of quality and consistency. Healthy demand for the product, coupled with a strong pricing environment, helped Grifols during the quarter.We continue to believe that Grifols will generate strong synergies from its 2011 acquisition of U.S.-based Talecris, and that Grifols will become significantly more profitable going forward. (Aaron Wasserman)
Check out Ron Baron latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 35.60
GRFS's P/E(ttm) is ranked higher than
72% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 34.10 vs. GRFS: 35.60 )
GRFS' s 10-Year P/E(ttm) Range
Min: 17.7   Max: 95
Current: 35.6

17.7
95
P/B 6.20
GRFS's P/B is ranked higher than
57% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.03 vs. GRFS: 6.20 )
GRFS' s 10-Year P/B Range
Min: 3.09   Max: 6.67
Current: 6.2

3.09
6.67
P/S 3.77
GRFS's P/S is ranked higher than
62% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.91 vs. GRFS: 3.77 )
GRFS' s 10-Year P/S Range
Min: 2.33   Max: 6.66
Current: 3.77

2.33
6.66
PFCF 30.20
GRFS's PFCF is ranked higher than
84% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 81.48 vs. GRFS: 30.20 )
GRFS' s 10-Year PFCF Range
Min: 21.36   Max: 1434
Current: 30.2

21.36
1434
EV-to-EBIT 20.82
GRFS's EV-to-EBIT is ranked higher than
77% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.61 vs. GRFS: 20.82 )
GRFS' s 10-Year EV-to-EBIT Range
Min: 14.6   Max: 68.3
Current: 20.82

14.6
68.3
PEG 1.20
GRFS's PEG is ranked higher than
95% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 121.00 vs. GRFS: 1.20 )
GRFS' s 10-Year PEG Range
Min: 0   Max: 2
Current: 1.2

0
2
Current Ratio 3.25
GRFS's Current Ratio is ranked higher than
80% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.77 vs. GRFS: 3.25 )
GRFS' s 10-Year Current Ratio Range
Min: 2.19   Max: 3.26
Current: 3.25

2.19
3.26
Quick Ratio 1.88
GRFS's Quick Ratio is ranked higher than
71% of the 302 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. GRFS: 1.88 )
GRFS' s 10-Year Quick Ratio Range
Min: 1.15   Max: 1.88
Current: 1.88

1.15
1.88

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.47
GRFS's Dividend Yield is ranked lower than
60% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. GRFS: 0.47 )
GRFS' s 10-Year Dividend Yield Range
Min: 0.48   Max: 0.6
Current: 0.47

0.48
0.6
Dividend Payout 0.15
GRFS's Dividend Payout is ranked higher than
57% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. GRFS: 0.15 )
GRFS' s 10-Year Dividend Payout Range
Min: 0.59   Max: 0.59
Current: 0.15

Yield on cost (5-Year) 0.50
GRFS's Yield on cost (5-Year) is ranked lower than
59% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.47 vs. GRFS: 0.50 )
GRFS' s 10-Year Yield on cost (5-Year) Range
Min: 0.48   Max: 0.6
Current: 0.5

0.48
0.6

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.90
GRFS's Price/Median PS Value is ranked higher than
71% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. GRFS: 0.90 )
GRFS' s 10-Year Price/Median PS Value Range
Min: 0.63   Max: 1.43
Current: 0.9

0.63
1.43
Earnings Yield (Greenblatt) 4.60
GRFS's Earnings Yield (Greenblatt) is ranked higher than
67% of the 252 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.30 vs. GRFS: 4.60 )
GRFS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.5   Max: 6.8
Current: 4.6

1.5
6.8

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare: » details
Traded in other countries:GIFLF.USA, GIKLY.USA, GRF.P.Spain, 0EM7.country, GRF.Spain, GIFOF.USA, G0FB.Germany, OZT.Germany
Grifols SA was founded in 1940 in Barcelona, Spain by Dr. José Antonio Grifols i Roig. The Company was incorporated in Spain as a limited liability company on June 22, 1987 under the name Grupo Grifols, S.A., and changed its name to Grifols, S.A. in 2005. The Company is a vertically integrated producer of plasma derivatives. Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers. The Company 150 FDA-licensed plasma collection centers located across the United States. It has expanded its plasma collection network through a combination of organic growth and acquisitions and the opening of new plasma collection centers. In 2012, it purchased three plasma collection centers in the United States from Cangene Corporation, a Canadian biopharmaceutical firm. The Company's products and services are used by healthcare providers in approximately 100 countries to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions, and we have a direct presence, through the operation of commercial subsidiaries, in 24 countries. Its business segments arte: Bioscience, Diagnostic and Hospital. The Bioscience division includes activities relating to the manufacture of plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation and purification of plasma, and the sale and distribution of end products. The Diagnostic division is engaged in researching, developing, manufacturing and marketing vitro diagnostics products, including analytical instruments and reagents for diagnostics, as well as blood bank products. The Hospital division manufactures and in certain instances installs products used by and in hospitals, such as parenteral solutions and enteral and parenteral nutritional fluids, which are sold almost exclusively in Spain and Portugal.
» More Articles for NAS:GRFS

Headlines

Articles On GuruFocus.com
Gold-Focused Guru John Paulson Reports First Quarter Holdings May 22 2014 
Is Grifols Being Overlooked? Mar 19 2014 
John Paulson's Top Five Holdings Nov 20 2013 
John Paulson's Top Five Holdings Sep 12 2013 
Baron Funds Comments on Grifols SA Aug 30 2012 
Friday Value Overview Aug 19 2011 

More From Other Websites
New highly sensitive test to screen donors of blood, tissues, and organs for Hepatitis E virus... Jul 25 2014
Nasdaq Leads Late Gains; S&P 500, Dow Erase Losses Jul 11 2014
Grifols SA Stock Upgraded (GRFS) Jul 08 2014
Stock Futures Point Lower; GasLog, Grifols, Kapstone Lag Jul 08 2014
Stocks Futures: Quiet And Mixed; Employers Hire Heavily In June Jul 03 2014
GRFS, OCR And A, 3 Health Services Stocks Pushing The Industry Lower Jul 02 2014
Award Winners at the Seventh Edition of the Martín Villar Research Awards Jul 01 2014
Grifols Struggles After Report Of Possible Violations Jun 25 2014
Weakness Seen in Alcobra (ADHD): Stock Falls 6.7% Jun 24 2014
Major Indexes Lower Near Midday; Matador Resources Rallies Jun 23 2014
Grifols shares off lows, remain down over 2% Jun 23 2014
3 Stocks Underperforming Today In The Health Services Industry Jun 19 2014
M&A Activity Helps Fuel Healthy Action In Drugmakers Jun 18 2014
Grifols opens state-of-the-art facility in Clayton, NC to help advance treatment of rare and... Jun 17 2014
Moats and Growth Drivers Look Solid for Post-Split Baxter Jun 15 2014
Stocks Hold Modest Gains; Anika Clears Late-Stage Base Jun 09 2014
Stocks Hold Gains; Grifols Breaks Out Jun 06 2014
Stocks Firm Up After Favorable Jobs Report Jun 06 2014
Stocks Open Ahead, Volume Mixed; Verifone, Angie's List Rocket Jun 06 2014
Trade-Ideas: Grifols (GRFS) Is Today's New Lifetime High Stock Jun 06 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide